Skip to main content

Table 1 Demographic and clinical characteristics of study population

From: Health-related quality of life among children with transfusion-dependent thalassemia: A cross-sectional study in Malaysia

Characteristics

N (%)

Age (years) (n = 368)

 2–4.9 years old

36 (9.78)

 5–7.9 years old

62 (16.85)

 8–12.9 years old

134 (36.41)

 13–18.9 years old

136 (36.96)

Gender (n = 368)

 Male

178 (48.37)

 Female

190 (51.63)

Ethnicity (n = 368)

 Malay

242 (65.85)

 Chinese

44 (11.92)

 Kadazan-Dusun

55 (14.91)

 Others

27 (7.32)

Region (n = 368)

 Northern (Penang, Perak)

43 (11.68)

 Central (Selangor, Federal Territory of Kuala Lumpur, Negeri Sembilan)

76 (20.65)

 Southern (Johore)

45 (12.23)

 East Coast (Pahang, Kelantan, Terengganu)

104 (28.26)

 East Malaysia (Sabah, Sarawak)

100 (27.17)

Education Level of Parents who completed Proxy-Report (n = 257)

 No Formal Education

12 (4.67)

 Primary or Secondary School

183 (71.20)

 Tertiary Education

62 (24.12)

Education Level of Children who completed Self-Report (n = 111)

 No Formal Education

3 (2.70)

 Primary or Secondary School

97 (87.39)

 Tertiary Education

11 (9.91)

Source of survey (n = 368)

 Self-reported

111 (30.16)

 Parent Proxy-reported

257 (69.84)

Presence of Iron Overload Complication (n = 368)

 Absent

267 (72.56)

 Present

101 (27.44)

 Endocrine Only

57 (15.49)

 Liver Only

24 (6.52)

 Cardiac Only

3 (0.82)

 Multi-system

20 (5.43)

Iron Chelation Therapy Route of Administration (n = 368)

 Subcutaneous Injection (SC)

42 (11.41)

 Oral (PO)

268 (72.83)

 Subcutaneous Injection (SC) + Oral (PO)

58 (15.76)

Iron Chelation Therapy (n = 368)

 SC Desferrioxamine

42 (11.41)

 PO Deferasirox

233 (63.32)

 PO Deferiprone

29 (7.88)

 SC Desferrioxamine + PO Deferiprone

41 (11.14)

 SC Desferrioxamine + PO Deferasirox

17 (4.62)

 PO Deferiprone + PO Deferasirox

6 (1.63)

Number of iron chelating agents (n = 368)

 Monotherapy

304 (82.61)

 Dual Therapy

64 (17.39)

History of Serious Adverse Event with Iron Chelation Therapy(n = 368)

 No

345 (93.75)

 Yes

23 (6.25)

Characteristics (N = 368)

Mean (SD)

Age (years)

10.59 (4.37)

Age at first transfusion (years)

2.66 (3.01)

Number of years receiving blood transfusion

7.68 (4.66)

  1. N number, SD standard deviation